PCOS: The Science Just Shifted. Here’s What You Need to Know

By Dr. Herman Weiss, MD, MBA, FACOG  —  Board-Certified OB/GYN · 25 Years Clinical Practice

hweissmd Substack  ·  The Metabolic Fix  ·  May 2026

I’ve been in clinical practice for 25 years. I’ve watched the PCOS conversation evolve — slowly, frustratingly slowly — from “just lose weight and your periods will regulate” to something far more nuanced, far more systemic, and far more urgent.

The last 12 months have been different. The research is finally catching up to what many of us have been seeing in our exam rooms for years. And some of it is changing how I diagnose, how I treat, and — honestly — how I talk to my patients about their long-term health.

Here’s what’s new, what’s proven, and what you should actually do about it.

1. PCOS Is Now Officially a Cardiovascular Risk Factor

This isn’t a footnote. This is a headline.

A landmark review published in Fertility & Sterility in September 2025, out of the University of Pennsylvania, confirmed what the cardiometabolic data has been pointing toward for years: PCOS confers elevated risk of heart attack and stroke even during the reproductive years. Not later. Now. [1]

The authors are explicit — PCOS should be classified as a cardiovascular disease risk-enhancing condition. Think about what that means in practice. We’re talking about the same category as chronic kidney disease and inflammatory arthritis. Yet most of my patients with PCOS have never had a lipid panel ordered by the physician who diagnosed them.

That needs to change.

The same paper highlights something I find genuinely fascinating: anti-Müllerian hormone (AMH) is no longer just a fertility marker. It’s emerging as a neuroactive hormone that may play a role in the brain-ovary signaling that drives PCOS itself. [1] We’ve been using AMH to count antral follicles for years. That framing is getting a lot more complicated — and a lot more interesting.

2. The Diagnostic Criteria Have Been Updated — And Simplified

The 2023 International Evidence-Based Guideline is now being widely implemented, and there are two things I want every clinician — and every patient who has felt dismissed — to know.

First: if a patient has both irregular cycles and hyperandrogenism, the diagnosis can be made clinically. No ultrasound required. No AMH required. Two cardinal features, case made. [2, 3]

Second: for adult women who don’t have both features, AMH can now serve as a direct alternative to transvaginal ultrasound for assessing polycystic ovarian morphology. That means a primary care physician can diagnose PCOS without specialized imaging — which removes a real access barrier for patients in underserved communities. [2]

The adolescent rules are deliberately more conservative. In teenagers, both hyperandrogenism and ovulatory dysfunction must be present. Ultrasound and AMH are not recommended in this group because too many normal adolescents would be over-diagnosed. [3] I appreciate the rigor there — we don’t want to label a 16-year-old with a condition that will follow her through her health record for life if we’re not sure.

The bottom line: diagnosing PCOS just got cleaner. Use the updated algorithm.

3. The Gut-Hormone Axis Is Real — And It’s Actionable

I’ve been talking about the gut microbiome in the context of women’s reproductive health for a while now, and I know it can sound like a stretch to some colleagues. It doesn’t sound like a stretch anymore.

A 2025 systematic review in Frontiers in Microbiologysynthesized both human and animal research on the gut microbiome in PCOS, and the picture is consistent. [4]Multiple independent studies are converging on one finding: women with PCOS have significantly reduced levels of Akkermansia muciniphila — a keystone gut bacterium that supports intestinal barrier integrity, regulates inflammation, and is directly tied to insulin sensitivity. [5]

Why does this matter for PCOS? Because the insulin-androgen cycle is the engine of the condition. Hyperinsulinemia drives excess androgen production by the ovarian theca cells. Anything that worsens insulin resistance — including gut dysbiosis — fans that flame.

There’s also a GLP-1 connection here. Gut-derived glucagon-like peptide-1 (GLP-1) stimulates insulin secretion from pancreatic beta-cells, suppresses glucagon, and slows gastric emptying. [6] When the gut microbiome is disrupted, GLP-1 production is impaired — which may be one of the reasons metabolic dysfunction clusters so reliably with the PCOS phenotype.

Probiotics and fermented foods aren’t alternative medicine in this context. They’re a mechanistically grounded intervention. I’m recommending them to my patients now.

4. GLP-1 Receptor Agonists in PCOS: The Evidence Is Getting Stronger

I get asked about semaglutide and liraglutide in PCOS constantly right now. The honest answer used to be: “promising, but the trials are small.” That answer is becoming less satisfying — because the trial data is maturing.

A November 2025 randomized controlled trial out of Huazhong University enrolled 60 overweight and obese women with PCOS and randomized them to metformin alone, liraglutide alone, or combination therapy for 12 weeks. [7] All three groups showed significant improvements in body weight, blood glucose, lipid profiles, and the LH/FSH ratio. The combination arm showed the most comprehensive metabolic and hormonal improvements.

What I find especially compelling is the parallel animal experiment in the same study, which showed that the combination of metformin plus liraglutide produced the most significant beneficial changes in gut microbiota composition. The metabolic and microbiome benefits appear to compound. [7]

This is consistent with an earlier network meta-analysis of 23 studies involving 951 women, which found that liraglutide monotherapy was superior to both orlistat and metformin for weight loss and waist circumference reduction in women with PCOS. [8]

Before initiating GLP-1 therapy in PCOS patients, screen for contraindications: history of pancreatitis, diabetic retinopathy, thyroid cancer. Plan for 6–12 months of monitoring. And have a real conversation with your patient about expectations — this isn’t a cure, it’s a metabolic lever. [8]

5. Inositols: Still First-Line, Now Better Understood

The 40:1 myo-inositol to D-chiro-inositol ratio has been a cornerstone of my PCOS supplement recommendations for years. Recent mechanistic work reinforces why this specific ratio matters.

In healthy ovarian follicles, myo-inositol is the dominant form — it’s essential for FSH signal transduction. Insulin drives the conversion of myo-inositol to D-chiro-inositol through an enzyme called epimerase. In insulin-resistant states — which describes most of my PCOS patients — this conversion goes haywire. You get excess D-chiro-inositol and a depletion of myo-inositol at the follicular level, which impairs egg quality and disrupts normal ovarian signaling. [4]

Supplementing at the 40:1 ratio restores physiologic follicular concentrations, improves oocyte quality, and consistently reduces androgen levels — without the GI side effects of metformin or the risks of other pharmaceutical insulin sensitizers.

Standard dosing I use: 4g myo-inositol + 100mg D-chiro-inositol daily, split into two doses. Most generic “PCOS supplements” on the market do not use this ratio. Read the label.

6. PCOS Is Systemic — And We Need to Treat It That Way

The most recent mechanistic research has confirmed what the clinical picture has always suggested: PCOS is not a disease of the ovary. It’s a systemic syndrome. [9]

Low-grade chronic inflammation, non-alcoholic fatty liver disease, oxidative stress, epigenetic dysregulation — these are not complications of PCOS. They’re features of it. Emerging therapeutic targets include advanced glycation end products (AGEs), sex hormone-binding globulin (SHBG), and microRNAs. None of these are in clinical protocols yet, but they represent the next wave. [9]

The implication for how we practice right now: no single intervention is enough. A woman who takes metformin but eats a highly processed diet, doesn’t sleep, and has an unaddressed gut dysbiosis is not being fully treated. The phenotype is heterogeneous. The treatment has to be too.

THIS WEEK’S ACTION PLAN

Evidence-based steps you can implement immediately.

IF YOU HAVE PCOS:

1. Get your AMH level checked — Not just for fertility. AMH is now a recognized marker of PCOS disease activity and neuroendocrine function. Ask your OB/GYN to include it in your workup.

2. Request a cardiovascular baseline — Fasting lipid panel, fasting glucose, fasting insulin (to calculate HOMA-IR), and blood pressure. PCOS is a cardiovascular risk enhancer. This conversation should be happening at diagnosis, not 20 years later.

3. Add one fermented food daily — Plain kefir, kimchi, or sauerkraut to begin rebuilding Akkermansia muciniphila and short-chain fatty acid production. Lowest-risk, most evidence-supported microbiome intervention available right now.

4. Check your inositol ratio — If you’re taking an inositol supplement, verify it’s 40:1 myo-inositol to D-chiro-inositol. Most off-the-shelf PCOS supplements aren’t formulated correctly. Standard dose: 4g myo-inositol + 100mg D-chiro-inositol daily, two divided doses.

5. Ask about GLP-1 eligibility — If you are overweight (BMI ≥27) with PCOS and haven’t responded adequately to lifestyle changes and/or metformin, ask your physician specifically about GLP-1 receptor agonist therapy. The evidence supports it.

IF YOU’RE A CLINICIAN:

6. Implement the updated 2023 diagnostic algorithm — Irregular cycles + hyperandrogenism = diagnosis. You don’t need the ultrasound. Simplify your workflow and reduce time to diagnosis.

7. Put PCOS on the cardiovascular risk radar — Document it, counsel it, add it to the problem list. It changes the monitoring calculus for the long term.

8. Order HOMA-IR — Fasting insulin remains underutilized. A HOMA-IR >2.5 identifies the insulin-resistant phenotype most likely to benefit from metformin, inositols, and GLP-1 therapy. Add it to your standard PCOS panel.

9. Consider GLP-1 + metformin combination — The November 2025 RCT supports this approach as superior for weight, lipids, and LH/FSH normalization in overweight PCOS women. The data is there.

10. Bring the gut into your lifestyle counseling — The microbiome data is strong enough now to include probiotic and fiber recommendations in your PCOS lifestyle guidance. Lactobacillus and Bifidobacterium species, plus prebiotic fibers (inulin, FOS), are where the evidence currently sits.

The bottom line is this: PCOS is converging on a systems-biology understanding that the best clinicians have intuitively held for years. The gut, the brain, the ovary, the heart — they are connected. The research is finally proving what we suspected.

We don’t have to wait for a new drug. The tools to meaningfully change outcomes for women with PCOS — diagnostically, metabolically, reproductively — exist today. The question is whether we’re using them.

I’m going to keep pushing until the standard of care catches up to the science.

— Dr. Herman Weiss, MD, MBA, FACOG CEO & Founder, ProvationLife™  |  Host, The Metabolic Fix

REFERENCES

[1]  Dokras A et al. "Polycystic ovary syndrome in 2025 — insights and innovations." Fertility & Sterility. Published online September 22, 2025. PubMed PMID: 40992713.

[2]  Teede HJ et al. "Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome." J Clin Endocrinol Metab. 2023;108(10):2447–2469. doi:10.1210/clinem/dgad463.

[3]  StatPearls. "Polycystic Ovarian Syndrome." Updated July 2025. National Library of Medicine. ncbi.nlm.nih.gov/books/NBK459251/

[4]  Hanna A et al. "Systematic review of gut microbiota composition, metabolic alterations, and the effects of treatments on PCOS and gut microbiota across human and animal studies." Front Microbiol. 2025;16:1549499. doi:10.3389/fmicb.2025.1549499.

[5]  Liu Y et al. "Gut microbiota: an emerging target connecting polycystic ovarian syndrome and insulin resistance." Front Cell Infect Microbiol. 2025;15:1508893. doi:10.3389/fcimb.2025.1508893.

[6]  Research Progress of Gut Microbiota and Its Metabolites in PCOS. Front Endocrinol. 2025;16:1700191. doi:10.3389/fendo.2025.1700191.

[7]  Long XF et al. "Combination metformin and liraglutide in PCOS: clinical efficacy in women and preclinical insights from gut microbiome modulation in rats." Front Endocrinol. Published November 26, 2025. doi:10.3389/fendo.2025.1599879.

[8]  Ghazi N et al. "Therapeutic Potential of Glucagon-like Peptide-1 Agonists in Polycystic Ovary Syndrome." Biomedicines. 2022;10:1989. doi:10.3390/biomedicines10081989. PMC9405922.

[9]  "The pathogenesis, therapeutic targets and drugs of polycystic ovary syndrome." Front Endocrinol. 2025. PMC12883396.

Dr. Herman Weiss, MD, MBA, FACOG  |  ProvationLife™  |  May 2026